Financial Data and Key Metrics Changes - In Q3, the company reported net revenue of $71.7 million, down 8% year-over-year, primarily due to lower ticketing revenue and the elimination of organizer fees, partially offset by a 38% increase in revenue from Eventbrite Ads [18][19] - Adjusted EBITDA was $8.4 million, representing a 58% year-over-year increase and an adjusted EBITDA margin of 11.7% [20] - Q3 net income was $6.4 million, a significant improvement from a net loss of $3.8 million in the previous year [20] Business Line Data and Key Metrics Changes - Paid ticket volume totaled 19.1 million, down 3% year-over-year, but showed a 400 basis points improvement from the 7% decline in Q2 [18] - Eventbrite Ads revenue grew 38% year-over-year, contributing positively to overall revenue despite the decline in ticketing revenue [18][19] Market Data and Key Metrics Changes - The company reported a nearly 4% increase in new paid creator acquisition in Q3, indicating a strengthening marketplace [8] - The average monthly users reached 92 million in Q3, with consumers and creators across 180 countries [9] Company Strategy and Development Direction - The company aims to stabilize paid ticket volumes and creator activity, with a focus on disciplined execution to support revenue growth and margin expansion in 2026 [6][10] - Strategic initiatives include enhancing creator tools, improving consumer engagement, and expanding market share globally [10][15] - The company plans to leverage AI for product innovation, focusing on premium tools for larger creators and enhancing consumer personalization [30][33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about operational momentum, expecting to return to monthly year-over-year paid ticket volume growth within the first few months of 2026 [23][24] - The company anticipates net revenue for Q4 to be between $71.5 million and $74.5 million, with an adjusted EBITDA margin of 8-9% [23] Other Important Information - Operating expenses were $49.6 million, down 20% year-over-year, marking the lowest level in four years [19] - The company ended the quarter with $511 million in cash and cash equivalents, with total debt reduced to $175 million [21] Q&A Session Summary Question: How is the company thinking about the right level of investment to drive growth in 2026? - Management emphasized a disciplined approach to operating expenses while reallocating funds to areas that drive growth, balancing cost reduction with investment in growth initiatives [26][28] Question: How does the company view the impact of GenAI on product innovation? - The company plans to focus on premium tools for larger creators, using AI to enhance marketing performance and consumer engagement, and expanding globally [30][33] Question: What is the company's stance on the ticketing ecosystem amid recent industry discussions? - The company aims to democratize the ticketing industry, advocating for fair pricing and transparency while continuing to invest in creator tools and consumer-friendly practices [36][38] Question: Can you provide insights on the sequential gross margin improvement and its implications? - Management expects modest continued improvement in gross margin, driven by the increasing contribution of higher-margin Eventbrite Ads to overall revenue [40][43]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $22.4 million, aligning with guidance, but $7 million lower compared to the prior year due to divestitures [14] - Adjusted EBITDA was $2.2 million, exceeding guidance, translating to a margin of 10%, marking the fifth consecutive quarter of adjusted EBITDA margins at or above 10% [4][17] - Annual recurring revenue (ARR) was $84.8 million, down from $92.2 million year-over-year, but showed a modest quarter-to-quarter increase of $100,000 [14][15] Business Line Data and Key Metrics Changes - Subscription revenue for Q3 2025 was $21.2 million, accounting for 94% of total revenue, slightly higher than the historical trend of 92% [14] - Corporate multi-year contracts for policy data now account for approximately 50% of new logo ARR, up from about 20% in early 2024, indicating a significant increase in revenue visibility [8] Market Data and Key Metrics Changes - Net revenue retention was 98%, level with the prior year and up 200 basis points over the second quarter on a pro forma basis [15] - The federal sector experienced volatility due to an extended government shutdown, with an estimated impact of $2 million to $3 million for the full year [32][33] Company Strategy and Development Direction - The company is focused on a product-led growth strategy, emphasizing the transition to the Policy Note platform and enhancing customer engagement through product innovation [9][10] - Management highlighted the importance of automation in operations to drive productivity and improve overall efficiency, with expectations for significant improvements in 2026 [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustainable growth and expanding profitability, despite ongoing challenges in the federal sector [11][19] - The company is encouraged by early traction and stabilization in the core business, with a focus on improving gross and net retention through enhanced product offerings [31] Other Important Information - The company updated its full-year revenue guidance to a range of $95-$96 million, with adjusted EBITDA projected to be approximately $10 million [12][18] - Cash and cash equivalents at the end of Q3 2025 were $31.8 million, providing sufficient liquidity to support ongoing operations and growth initiatives [17] Q&A Session Summary Question: Can you provide more color on the increase in average contract values (ACV)? - The increase in ACVs is primarily driven by leveraging global data more effectively, which has extended use cases through the enterprise [21] Question: Has there been any change in churn during the migration to Policy Note? - There has not been any meaningful migration-related churn, with positive experiences reported during the transition [22] Question: What are the expectations for renewed year-over-year ARR growth? - Specific guidance on ARR was not provided, but management is encouraged by the progress and transformation seen through Policy Note [30] Question: Can you quantify the impact of the federal government shutdown? - The estimated overall impact of the shutdown is between $2 million and $3 million for the full year [33]

Open Lending (NasdaqGM:LPRO) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker2Today, everyone, and welcome to the Open Lending Q3 2025 earnings conference call. At this time, all participants are in a listen-only mode. You will have the opportunity to ask questions during the question-and-answer session. You may register to ask questions by pressing the Star and 1 on your telephone keypad. You may withdraw your question from the queue by pressing Star 2. Please note this call is being recorded, a ...

nLIGHT (NasdaqGS:LASR) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker3Ladies and gentlemen, thank you for joining us, and welcome to the nLIGHT fourth quarter 2025 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press star 9 to raise your hand and star 6 to unmute. I will now hand the conference over to John Marchetti, VP, Corporate Development and ...

Financial Data and Key Metrics Changes - Innodata reported record revenue of $62.6 million for Q3 2025, representing a 20% year-over-year organic growth and a 7% sequential growth [4][23] - Adjusted EBITDA was $16.2 million, or 26% of revenue, up 23% sequentially, indicating margin expansion despite growth investments [4][23] - Cash increased to $73.9 million, up by $27 million since year-end and $14.1 million since last quarter [4][23] - Net income for Q3 2025 was $8.3 million, a decrease from $17.4 million a year ago, primarily due to a tax benefit from net operating loss carry forward in Q3 2024 [23] Business Line Data and Key Metrics Changes - The company is experiencing strong deal momentum with big tech customers, forecasting growth from six out of eight major clients [5][6] - New initiatives in 2025, including the creation of pre-training data at scale, are expected to generate approximately $68 million in potential revenue [8][9] Market Data and Key Metrics Changes - The launch of Innodata Federal aims to deliver AI solutions to U.S. defense and intelligence agencies, with an initial project expected to generate around $25 million in revenue [9][10] - The company is engaging with sovereign AI entities globally, indicating a growing interest in AI services across various regions [12][13] Company Strategy and Development Direction - The company is focused on deepening relationships with high-value tech customers and expanding into new markets, including federal and sovereign AI [5][9] - Six strategic investment areas have been identified for 2025, including pre-training data, model safety, and enterprise AI, which are expected to drive growth in 2026 [16][20] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for 45% or more year-over-year growth in 2025, with expectations for transformative growth in 2026 [4][23] - The federal government's emphasis on AI and streamlined procurement processes present a favorable environment for Innodata's growth [29] Other Important Information - The company appointed new board members with expertise in digital transformation and defense, enhancing its leadership for future growth [18] - Innodata was ranked No. 24 on Time Magazine's list of America's Top 500 Growth Leaders for 2026, highlighting its ability to capture trends [19] Q&A Session Summary Question: Potential contract wins and their impact on 2026 - Management indicated that annualized recurring revenue from contracts mentioned would primarily contribute to 2026 [24] Question: Incremental SG&A spending explanation - The $8.2 million in incremental SG&A is year-over-year compared to 2024 [25] Question: Stability of the relationship with the largest customer - The relationship is strong and stable, with potential for significant new programs [26][27] Question: Federal market win and GSA process - The timing for entering the federal market is ideal due to government prioritization of AI and procurement liberalizations [28][29] Question: Services market potential compared to model builder market - The enterprise services market is expected to be significantly larger than the model builder market, with early deployments showing cost reductions for clients [30]

The Joint Corp (NasdaqCM:JYNT) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker1Today, and welcome to The Joint Corporation Third Quarter 2025 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch-tone phone. To withdraw your q ...

Motorsport Games (NasdaqCM:MSGM) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker2Thank you for standing by and welcome to Motorsport Games' third quarter 2025 earnings call. As a reminder, today's conference is being recorded. I would like to turn the conference over to Ben Rossiter-Turner from Motorsport Games. Please go ahead.Speaker3Thank you and welcome to Motorsport Games' third quarter 2025 earnings conference call and webcast. On today's call is Motorsport Games' Chief Executive Officer S ...

Veritone (NasdaqGM:VERI) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker1Good day, and welcome to the Veritone Third Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, pleas ...

Eastman Kodak Company (NYSE:KODK) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker1Good day, and thank you for standing by. Welcome to the Eastman Kodak quarter 3 2025 earnings conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to the first speaker today, Anthony Redding. Please go ahead.Speaker3Thank you, and good afternoon, everyone. Welcome to Kodak's Third Quarter ...

Financial Data and Key Metrics Changes - For Q3 2025, the company reported net revenues of $191.8 million, a slight increase from $191.2 million in the previous year [10] - GAAP net income was $17.3 million, or $0.37 per diluted share, down from $40.4 million, or $0.78 per diluted share in Q3 2024 [15] - Adjusted net income decreased to $44.6 million, or $0.93 per diluted share, compared to $49.6 million, or $0.96 per diluted share in the prior year [15] - Gross margins declined to 51.4% from 53.3% in the previous year's period [12] Business Line Data and Key Metrics Changes - Vaccimi sales reached $53.6 million, up 14% year-over-year from $40.4 million [10][11] - Primatene Mist sales increased by 11% to $28.8 million from $26.1 million [10] - Glucagon injection sales fell 49% to $13.6 million due to decreased unit volumes and increased competition [11] - Epinephrine sales decreased 12% to $18.8 million, while lidocaine sales dropped 19% to $12.9 million [11] - Other pharmaceutical product sales rose to $64.1 million from $58.3 million, driven by increased albuterol sales and the launch of iron sucrose injection [11] Market Data and Key Metrics Changes - The company is positioned to capture a combined market opportunity of over $60 billion with its newly added assets in oncology and ophthalmology [5] - The market for wet age-related macular degeneration and diabetic macular edema is valued at $9.4 billion [5] Company Strategy and Development Direction - The company is focused on a vertically integrated strategy and expanding its proprietary pipeline, aiming for proprietary products to comprise 50% of its pipeline by 2026 [6] - A significant expansion in US manufacturing capacity is planned to quadruple production at its Rancho Cucamonga headquarters [5] - The company is advancing its regulatory initiatives, including the FDA approval of iron sucrose injection, which is now commercially available [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving flat year-over-year revenue for the current year, with expectations of high single-digit to low double-digit growth for the next year [20] - The company is optimistic about the long-term growth potential of Vaccimi, forecasting peak sales of $250 million to $275 million [44] Other Important Information - The company has entered into an exclusive in-licensing agreement with Nanjing Anji Biotechnology for three early-stage peptide candidates [4] - A litigation provision related to a recent jury verdict has significantly impacted general and administrative expenses [13] Q&A Session Summary Question: Updated thoughts on year-over-year top line and growth for next year - Management believes they can achieve flat revenue this year and anticipates high single-digit to low double-digit growth next year [20] Question: Opportunity size for iron sucrose - The current run rate for iron sucrose is approximately $2.4 million, which is expected to stabilize [20] Question: Updates on AMP007 and FDA communication - Engagement with the FDA continues, with slight delays in interactions but no missed dates reported [23] Question: Competitive dynamics for generic Venofer - The company aims to launch iron sucrose with a profitable price portfolio and is adjusting guidance for next year based on risk [27] Question: Licensing with Nanjing Anji and business development appetite - The company is excited about the new peptide candidates and is looking for either commercialized or late-stage R&D assets in future deals [32] Question: Competitive landscape for insulin aspart - The company expects to face three or more competitors in the insulin aspart market but believes it will still be a significant opportunity [35] Question: Competition for Primatene Mist post-patent expiration - Management does not anticipate immediate competition for Primatene Mist but acknowledges the potential for generic entries [36] Question: Development path for in-licensed products - The new chemical products will follow the standard regulatory pathway, with some expected to have shorter paths to market [39]